Home    Back

Stargen    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
301Macular dystrophy1

301. Macular dystrophy    [ 41 clinical trials,   47 drugs,   (DrugBank: 12 drugs),   12 drug target genes,   66 drug target pathways]
Searched query = "Macular dystrophy", "Best disease", "Stargardt disease", "Cone dystrophy", "Cone rod dystrophy", "X-linked juvenile retinoschisis", "Central areolar choroidal dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 41 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2010-023111-34-FR
(EUCTR)		18/07/201108/03/2012A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration.A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration. Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease.Product Name: StarGen
Product Code: Lentiviral vector containing ABCA4 gene
INN or Proposed INN: StarGen		Oxford BioMedica (UK) LtdNULLNot RecruitingFemale: yes
Male: yes		28Phase 1;Phase 2France;Netherlands;Italy